ID   MOLM-1
AC   CVCL_2118
SY   MOLM1
DR   cancercelllines; CVCL_2118
DR   CGH-DB; 9222-4
DR   Cosmic; 787504
DR   Cosmic; 798670
DR   Cosmic; 919133
DR   Cosmic; 994172
DR   Cosmic; 996324
DR   Cosmic; 998756
DR   Cosmic; 999776
DR   Cosmic; 1037676
DR   Cosmic; 2089677
DR   Cosmic; 2378087
DR   DepMap; ACH-001573
DR   DSMZ; ACC-720
DR   DSMZCellDive; ACC-720
DR   JCRB; JCRB1808
DR   Wikidata; Q54906316
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   PubMed=1782185;
RX   PubMed=9510473;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=10695022;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=23955599;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~43 hours (PubMed=1782185); ~60-70 hours (DSMZ=ACC-720).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 13 fused to ABL1 exon 2 (b2a2 transcript) (PubMed=1782185; PubMed=10071072; PubMed=10576511).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (DepMap=ACH-001573).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DepMap=ACH-001573; DSMZ=ACC-720; JCRB=JCRB1808
ST   Amelogenin: X
ST   CSF1PO: 8
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 17
ST   D19S433: 13
ST   D21S11: 30,31
ST   D2S1338: 17,24
ST   D3S1358: 16,17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 10,12 (DepMap=ACH-001573)
ST   D8S1179: 12 (DSMZ=ACC-720)
ST   FGA: 23,24
ST   Penta D: 10 (DSMZ=ACC-720)
ST   Penta D: 10,14 (DepMap=ACH-001573)
ST   Penta E: 14,19
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 14,17
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   PubMed=1782185;
RA   Matsuo Y., Adachi T., Tsubota T., Imanishi J., Minowada J.;
RT   "Establishment and characterization of a novel megakaryoblastic cell
RT   line, MOLM-1, from a patient with chronic myelogenous leukemia.";
RL   Hum. Cell 4:261-264(1991).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=10695022;
RA   Matsuo Y., Nishizaki C., Drexler H.G.;
RT   "Efficient DNA fingerprinting method for the identification of
RT   cross-culture contamination of cell lines.";
RL   Hum. Cell 12:149-154(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000), 255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//